Conv. Plasma
Nigella Sativa
Peg.. Lambda

All favipiravir studies
Meta analysis
Home COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -17% Improvement Relative Risk Mortality, day 30 14% Ventilation time -47% ICU time -50% Favipiravir  Sulaiman et al.  ICU PATIENTS Is very late treatment with favipiravir beneficial for COVID-19? PSM retrospective 146 patients in Saudi Arabia (Mar 2020 - Jul 2021) Longer ventilation (p=0.008) and ICU admission (p=0.01) Sulaiman et al., J. Infection and Publ.., Jun 2023 Favors favipiravir Favors control

When Antivirals Backfire: An Evaluation of Favipiravir’s Clinical Outcomes in Critically Ill Patients with COVID-19: A Multicenter Cohort Study

Sulaiman et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2023.06.011
Jun 2023  
  Source   PDF   All Studies   Meta AnalysisMeta
PSM retrospective 1,218 COVID-19 ICU patients in Saudi Arabia, showing no significant difference in mortality, and longer ICU/MV time with favipiravir treatment. This study is excluded in the after exclusion results of meta analysis: very late stage, ICU patients.
risk of death, 17.0% higher, HR 1.17, p = 0.51, treatment 73, control 73, in-hospital, propensity score matching.
risk of death, 14.0% lower, HR 0.86, p = 0.53, treatment 73, control 73, propensity score matching, day 30.
ventilation time, 46.7% higher, relative time 1.47, p = 0.008, treatment 73, control 73, propensity score matching.
ICU time, 50.0% higher, relative time 1.50, p = 0.01, treatment 73, control 73, propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sulaiman et al., 14 Jun 2023, retrospective, Saudi Arabia, peer-reviewed, mean age 60.1, 20 authors, study period 1 March, 2020 - 31 July, 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
When Antivirals Backfire: An Evaluation of Favipiravir’s Clinical Outcomes in Critically Ill Patients with COVID-19: A Multicenter Cohort Study
Khalid Al Sulaiman, Ohoud Aljuhani, Ghazwa B Korayem, Ali F Altebainawi, Mashael Alfaifi, Majed Nahari, Alaa Almagthali, Abrar K Thabit, Raghad Alhajaji, Reham Alharbi, Khawla Kahtani, Abeer A Alenazi, Aisha Alharbi, Munirah M Alghwainm, Sara M Alotaibi, Yazeed S Alghamdi, Samar Alotaibi, Shaden H Alonazi, Jumanah M Almutairi, Ramesh Vishwakarma
Journal of Infection and Public Health, doi:10.1016/j.jiph.2023.06.011
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Author Contributions All authors agreed to be fully accountable for ensuring the integrity and accuracy of the work and read and approved the final manuscript. Ethical Approval and Informed Consent Statement The study protocol was reviewed and approved by the Institutional Review Board of King J o u r n a l P r e -p r o o f Conflicts of interest The authors declare no conflict of interest. Declaration of Competing Interest We have no conflict of interest to declare. J o u r n a l P r e -p r o o f
Al-Muhsen, Ns, Sharif-Askari, Basamh, Alyounes et al., Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia, Front Med, doi:10.3389/fmed.2022.826247
Alamer, Alrashed, Alfaifi, Alosaimi, Alhassar et al., Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis, Curr Med Res Opin, doi:10.1080/03007995.2021.1920900
Alhazzani, Alshahrani, Alshamsi, Aljuhani, Eljaaly et al., The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section, J Infect Public Health, doi:10.1016/j.jiph.2021.10.005
Aljuhani, Sulaiman, Alshabasy, Eljaaly, Shaya et al., Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study, BMC Infect Dis J o u r n a l P r e -p r o o f, doi:10.1186/s12879-021-06813-1
Arabia, Saudi MoH Protocol for Adults Patients Suspected of / Confirmed with COVID-19 Supportive care and antiviral treatment of suspected or confirmed COVID-19 infection
Ford, Vitoria, Rangaraj, Norris, Calmy et al., Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment, J Int AIDS Soc, doi:10.1002/jia2.25489
Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc Japan Acad Ser B Phys Biol Sci, doi:10.2183/pjab.93.027
Furuta, Takahashi, Shiraki, Sakamoto, Smee et al., T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral J, Antiviral Res, doi:10.1016/j.antiviral.2009.02.198
Guner, Hasanoglu, Kayaaslan, Aypak, Akinci et al., Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir, J Infect Public Health, doi:10.1016/j.jiph.2020.12.017
Harbi, Kensara, Aljuhani, Korayem, Altebainawi et al., Statins and Risk of Thrombosis in Critically ill Patients with COVID-19: A Multicenter Cohort Study, Clin Appl Thromb, doi:10.1177/10760296221103864
Hassanipour, Arab-Zozani, Amani, Heidarzad, Fathalipour et al., The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials, Sci Rep, doi:10.1038/s41598-021-90551-6
Helmy, Fawzy, Elaswad, Sobieh, Kenney et al., The COVID-19 pandemic: A comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control, J Clin Med, doi:10.3390/jcm9041225
Irie, Nakagawa, Fujita, Tamura, Eto et al., Population pharmacokinetics of favipiravir in patients with COVID-19, CPT Pharmacometrics Syst Pharmacol, doi:10.1002/psp4.12685
Jang, Jeon, Kim, Sy, Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay, Proc Natl Acad Sci U S A, doi:10.1073/pnas.2024302118
Lan, Lai, Chang, Lu, Hung et al., Favipiravir-based treatment for outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials, Expert Rev Clin Pharmacol, doi:10.1080/17512433.2022.2078701
Manabe, Kambayashi, Akatsu, Kudo, Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis, BMC Infect Dis, doi:10.1186/s12879-021-06164-x
Munir, Kuganda, Basry, The efficacy and safety of antivirus drugs for COVID-19: A systematic review, Syst Rev Pharm, doi:10.31838/srp.2020.7.26
Qomara, Primanissa, Amalia, Purwadi, Zakiyah, Effectiveness of remdesivir, lopinavir/ritonavir, and favipiravir for COVID-19 treatment: A systematic review, Int J Gen Med, doi:10.2147/IJGM.S332458
Scape, Saudi, None, Critical Care Pharmacy Research
Solaymani-Dodaran, Ghanei, Bagheri, Qazvini, Vahedi et al., Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia, Int Immunopharmacol, doi:10.1016/j.intimp.2021.107522
Sulaiman, Aljuhani, Eljaaly, Alharbi, Shabasy et al., Clinical features and outcomes of critically ill patients with coronavirus disease 2019 (COVID-19): A multicenter cohort study, Int J Infect Dis, doi:10.1016/j.ijid.2021.02.037
Sulaiman, Aljuhani, Korayem, Hafiz, Alalawi et al., Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study, Thromb J, doi:10.1186/s12959-022-00432-9
Sulaiman, Aljuhani, Shaya, Kharbosh, Kensara et al., Evaluation of zinc sulfate as an adjunctive therapy in COVID-19 critically ill patients: a two center propensity-score matched study, Crit Care, doi:10.1186/s13054-021-03785-1
Sulaiman, Korayem, Altebainawi, Harbi, Alharthi, Evaluation of inhaled nitric oxide (iNO) treatment for moderate-to-severe ARDS in critically ill patients with COVID-19: a multicenter cohort study, Crit Care, doi:10.1186/s13054-022-04158-y
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Wang, Paulson, Pease, Watson, Comfort et al., Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, Lancet, doi:10.1016/S0140-6736(21)02796-3
Wang, Zhong, Salam, Tarning, Zhan et al., Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza, J o u r n a l P r e -p r o o f Total Bilirubin, doi:10.1016/j.ebiom.2020.103125
Yang, Zeng, Dai, Chen, Yang, A systematic review and Bayesian network meta-analysis for comparative safety assessment of favipiravir interventions in hospitalized COVID-19 patients, J Infect Dev Ctries, doi:10.3855/jidc.16083
Özlüşen, Kozan, Akcan, Kalender, Yaprak et al., Effectiveness of J o u r n a l P r e -p r o o f favipiravir in COVID-19: a live systematic review, Eur J Clin Microbiol Infect Dis, doi:10.1007/s10096-021-04307-1
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop